Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy

AIDS

Volumn 21, Issue 8, 2007, Pages 939-946

  Huttner, Angela C ^a   Kaufmann, Gilbert R ^b   Battegay, Manuel ^b   Weber, Rainer ^a   Opravil, Milos ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CD4 cell percentage; CD4 cell recovery; Cohort study; Potent antiretroviral therapy; Zidovudine

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 34247647464     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280f00fd6     Document Type: Article

References (32)

1. Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998; 12:1513-1519.
2. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14:1591-1600.
3. Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000; 14:1601-1610.
4. French M, Amin J, Roth N, Carr A, Law M, Emery S, et al. Randomized, open-label comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 Study. HIV Clin Trials 2002; 3:177-185.
5. Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut J, Goujard C, et al. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in HIV-infected nucleoside- experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors. Antimicrob Agents Chemother 2002; 46:1906-1913.
6. Amin J, Moore A, Carr A, French MA, Law M, Emery S, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleosides reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003; 4:252-261.
7. Negredo E, Paredes R, Peraire J, Pedrol E, Cote H, Gel S, et al. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Antivir Ther 2004; 9:889-893.
8. Gandhi RT, Spritzler J, Chan E, Asmuth D, Rodriguez B, Merigan T, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-434.
9. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al., for the CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046.
10. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al., Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
11. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-869.
12. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-197.
13. Tough DF, Sprent J. Life span of naive and memory T cells. Stem Cells 1995; 13:242-249.
14. Munch-Petersen B. Azidothymidine inhibits mitogen stimulated growth and DNA-repair in human peripheral lymphocytes. Biochem Biophys Res Commun 1988; 157:1369-1375.
15. Yarchoan R, Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med 1987; 316:557-564.
16. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-2226.
17. Pozniak AL, Gallant JE, Dejesus E, Arribas JR, Gazzard B, Campo RE, et al., for the Study 934 Group. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
18. Goicoechea M, Haubrich R. CD4 lymphoctye percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 2005; 192:945-947.
19. 3. J Infect Dis 2005; 192:950-957.
20. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1028-1033.
21. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel F, et al. Relationship between antiretrovirals used as part of a HAART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-1150.
22. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14:2635-2642.
23. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the Eurosida Study. J Infect Dis 2001; 183:1290-1294.
24. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
25. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al., Italian Cohort Naive Antiretrovirals Study Group. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
26. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
27. Kaufmann G, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-Lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years. Arch Intern Med 2003; 163:2187-2195.
28. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al., EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
29. Friedl A, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. AIDS 2001; 15:1793-1800.
30. 6/l. AIDS 2002; 16:1371-1381.
31. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064.
32. Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005; 19:1183-1188.